by Alex Kadhim
Researchers at Imperial College London and the University of Oxford have found a bispecific CD19 and CD133 chimeric antigen receptor (CAR) engineered into invariant natural killer T cells can...
by Alex Khadhim
Researchers at Friedrich-Alexander-Universität Erlangen–Nürnberg and Universitätsklinikum Erlangen have found that autologous CD19 CAR T cell therapy can induce rapid, drug-free clinical...
by ASTCT
The following infographics are based on ASTCT's December 2, 2026 webinar in which Dr. Michael D. Jain (Moffitt Cancer Center) and Dr. Stephen Gottschalk (St. Jude Children’s...
by Kevin McNerney, MD
Kevin McNerney, MD, is the first author of the article “Management practices of CAR T-cell-related inflammatory toxicities: a survey of pediatric CAR T-cell providers.” He shares in...
by Alex Kadhim
Researchers at McMaster University, collaborating with the Ottawa Hospital Research Institute, have found that a paired vaccine plus CAR strategy can broadly boost adoptively transferred T cells...
by Alex Khadhim
Researchers at University Hospital of Leipzig and Memorial Sloan Kettering Cancer Center have demonstrated that the BCMA CAR T product ciltacabtagene autoleucel appears to deliver deeper and...